Participants 432 579 6
Eighty-eight chemotherapy-na√Øve metastatic pancreatic cancer patients were randomized for treatment with gemcitabine or gemcitabine plus erlotinib
Participants 1408 1483 5
 metastatic pancreatic cancer patients, especially those with EGFR mutation
